<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382694</url>
  </required_header>
  <id_info>
    <org_study_id>NMSG#13/03</org_study_id>
    <nct_id>NCT00382694</nct_id>
  </id_info>
  <brief_title>Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients</brief_title>
  <official_title>Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients: A Randomised, Placebo Controlled, Double Blind Phase II Trial: NMSG #13/03</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Myeloma Study Group</source>
  <brief_summary>
    <textblock>
      Multiple myeloma is an incurable malignant disease which evnetuelly will relapse after&#xD;
      primary treatment. Clonal B-cells have been identified and in theory these cells might be&#xD;
      sleeping during primary treatment and be responsible for later relapse. Fluarabine has&#xD;
      documented effect on both resting and dividing cells including B-cells. The protocol aim at&#xD;
      evaluating safety and toxicity of adding fludarabine to induction chemotherapy with&#xD;
      cyclophosphamide and dexamethasone before high-dose melphalan with autologous stem cell&#xD;
      support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, placebo controlled, phase II study evaluating toxicity and safety of&#xD;
      fludarabine added to CyDex (cyclophosphamide+dexamethasone) as induction therapy in younger&#xD;
      patients with untreated and treatment demanding multiple myeloma. The treatment regimen&#xD;
      Patients will be randomised at diagnosis either to CyDex + Placebo (control Arm A) or CyDex +&#xD;
      Fludarabine (Experimental Arm B).&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
        -  Primary:To determine the toxicity and safety of fludarabine when added to induction&#xD;
           therapy by registration of side effects and adverse events in accordance with the common&#xD;
           toxicity criteria (CTC).&#xD;
&#xD;
        -  Secondary:To quantitate clonal cells in bone marrow and blood by flow cytometry (MRD)and&#xD;
           to study new potential prognostic markers identified by cytomic, genomic and proteomic&#xD;
           analysis.&#xD;
&#xD;
        -  Tertiary: To estimate the efficacy of fludarabine when added to induction&#xD;
           chemotherapy(CyDex) in patients with multiple myeloma by clinical end points: disease&#xD;
           response and progression free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The toxicity and safety of Fludarabine when added to induction therapy by registration of side effects and adverse events in accordance with the common toxicity criteria (CTC).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of clonal cells in bone marrow and blood by flow cytometry (MRD) and to study new potential prognostic markers identified by cytomic, genomic and proteomic analysis.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the efficacy of Fludarabine when added to induction chemotherapy (CyDex) in patients with multiple myeloma by clinical end points: disease response and progression free survival</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple myeloma, stage I-III, previously untreated, and eligible for induction&#xD;
             therapy followed by high dose treatment supported by autologous stem cell&#xD;
             transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe uncontrolled clinical or microbiological evidence of infection at the time of&#xD;
             enrolment.&#xD;
&#xD;
          -  Other active malignancy.&#xD;
&#xD;
          -  Severe coincident heart or lung disease including uncontrolled hypertension, unstable&#xD;
             angina, congestive heart failure, coronary angioplasty within six months, myocardial&#xD;
             infarction within the last six months, or uncontrolled cardiac arrhythmia.&#xD;
&#xD;
          -  Other severe illness including poorly controlled diabetes.&#xD;
&#xD;
          -  Haemolytic anaemia (Coombs positive without evidence of haemolysis is accepted).&#xD;
&#xD;
          -  Idiopathic thrombocytopenic purpura.&#xD;
&#xD;
          -  Terminal illness.&#xD;
&#xD;
          -  Allogenic transplantation planned within 6 months.&#xD;
&#xD;
          -  Chemotherapy before inclusion.&#xD;
&#xD;
          -  Pregnancy or breast-feeding, or inadequate contraceptive precautions.&#xD;
&#xD;
          -  Psychiatric disease, abuse of alcohol or narcotics, or any other disorder that might&#xD;
             compromise the patients ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans E. Johnsen, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Univeristy Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Haematology B, Aalborg Hospital, University of Aarhus</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology X, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Haematology, Århus University Hospital</name>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 28, 2006</study_first_submitted>
  <study_first_submitted_qc>September 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2006</study_first_posted>
  <last_update_submitted>September 28, 2006</last_update_submitted>
  <last_update_submitted_qc>September 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2006</last_update_posted>
  <keyword>Myeloma</keyword>
  <keyword>Induction therapy</keyword>
  <keyword>High-dose melphalan</keyword>
  <keyword>Autologous stem cell support</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Safety</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

